Efficacy and safety of PARP inhibitors monotherapy or combination therapy with anti-angiogenics in ovarian cancer: a network meta-analysis
Yuan Liu, Tongtong Ren, Xinchun Wang, Yuqi Wang, Lisha Tang, Wenjiang Cao · 2026
Read Efficacy and safety of PARP inhibitors monotherapy or combination therapy with anti-angiogenics in ovarian cancer: a network meta-analysis by Yuan Liu, Tongtong Ren, Xinchun Wang, Yuqi Wang, Lisha Tang, Wenjiang Cao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12883406.txt.
Description
Yuan Liu and co-authors pool trial results to rank drug plans for ovarian cancer, in an analysis whose head dates it to 2025. One drug family blocks a repair path in cancer cells, and a second family cuts tumor blood supply. The team searched major databases to the end of 2024 and merged fifteen trials with more than six thousand patients across nine plans.
All plans with the repair blocking drugs beat dummy care on time with no growth of the cancer. Pairs beat single drugs on that score, and one pair ranked first of all. A second pair ranked next. Harsh side effects ran at like rates for single drugs but rose when drugs were paired. The authors urge plans matched to each patient, since gain and harm rise together.
Catalog record
| CREATOR | Yuan Liu, Tongtong Ren, Xinchun Wang, Yuqi Wang, Lisha Tang, Wenjiang Cao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |